Harvoni (ledipasvir and sofosbuvir) for hepatitis C

Nurse Practitioner

Volumn 40, Issue 11, 2015, Pages 22-26

  Mullins, Caitlin ^a   Gibson, Whitney ^b   Klibanov, Olga M ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b WINGATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ANALOGS AND DERIVATIVES; CONTRAINDICATIONS; DRUG INTERACTION; HEPATITIS C; HUMAN; NURSE PRACTITIONER; NURSING; PATIENT EDUCATION; PRACTICE GUIDELINE;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG INTERACTIONS; FLUORENES; HEPATITIS C; HUMANS; NURSE PRACTITIONERS; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; URIDINE MONOPHOSPHATE;

EID: 84955398470     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000472253.59198.1c     Document Type: Article

References (11)

1. World Health Organization. Health topics: hepatitis. www.who.int/mediacentre/factsheets/ fs164/en/.
2. The Centers for Disease Control and Prevention. Viral Hepatitis Statistics & Surveillance. 2014. www.cdc.gov/hepatitis/Statistics/2012Surveillance/ Commentary.htm.
3. The Recommendations for Testing, Managing, and Treating Hepatitis C. http://hcvguidelines. org/full-report-view.
4. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-1444.
5. Gilead Sciences, Inc. HARVONI prescribing information. Foster City, CA: Gilead Sciences. 2015. www.gilead.com/~/media/Files/pdfs/ medicines/liver-disease/harvoni/harvoni-pi.pdf.
6. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
7. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
8. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888.
9. United States Food and Drug Administration (FDA). FDA Approved Drug Products. www. accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.DrugDetails.
10. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodefi ciency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis. 2002;34(6):831-837.
11. Gilead Sciences Harvoni Support Path. https:// www.harvoni.com/support.